Q2 EPS Estimates for TScan Therapeutics Cut by Wedbush

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Analysts at Wedbush reduced their Q2 2025 EPS estimates for shares of TScan Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.26) per share for the quarter, down from their previous forecast of ($0.25). Wedbush currently has a “Outperform” rating and a $7.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics’ Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.94) EPS, FY2027 earnings at ($0.99) EPS, FY2028 earnings at ($0.92) EPS and FY2029 earnings at ($0.91) EPS.

A number of other equities research analysts also recently commented on TCRX. Needham & Company LLC reiterated a “buy” rating and set a $9.00 price target on shares of TScan Therapeutics in a report on Tuesday, April 8th. HC Wainwright lowered their price objective on TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday. Morgan Stanley reaffirmed an “overweight” rating and set a $10.00 price objective on shares of TScan Therapeutics in a research note on Friday, March 14th. Finally, Barclays dropped their price target on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Six analysts have rated the stock with a buy rating, According to MarketBeat, TScan Therapeutics currently has an average rating of “Buy” and a consensus price target of $8.50.

TScan Therapeutics Stock Down 6.9 %

Shares of NASDAQ:TCRX opened at $1.29 on Friday. The company has a market capitalization of $72.72 million, a P/E ratio of -1.21 and a beta of 1.06. The stock’s fifty day simple moving average is $1.49 and its 200-day simple moving average is $2.72. TScan Therapeutics has a 52-week low of $1.02 and a 52-week high of $9.69. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.62 million.

Institutional Investors Weigh In On TScan Therapeutics

Several institutional investors have recently bought and sold shares of TCRX. Barclays PLC raised its position in TScan Therapeutics by 341.1% in the third quarter. Barclays PLC now owns 58,067 shares of the company’s stock valued at $289,000 after purchasing an additional 44,903 shares during the period. JPMorgan Chase & Co. increased its stake in TScan Therapeutics by 94.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 31,805 shares of the company’s stock worth $158,000 after buying an additional 15,441 shares during the period. SG Americas Securities LLC lifted its holdings in TScan Therapeutics by 31.2% in the 4th quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock worth $62,000 after buying an additional 4,852 shares in the last quarter. Heck Capital Advisors LLC purchased a new position in TScan Therapeutics in the 4th quarter valued at about $61,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of TScan Therapeutics during the fourth quarter worth about $32,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.